KMPH KemPharm Inc.

$-100%

1,838,082 Shares Traded
133,066 Average Volume (last 30 days)

as of February 23, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $1.19 million
If Intiated on the First, Shorts Have Realized a Year to Date Return of:-26.8%
If Intiated One Month Ago, Shorts Have Realized a Return of:6.87%
If Initiated Five Days ago, Shorts Have Realized a Return of:6.87%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bearish
50 Day Moving Average Indicator Bearish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 1.53%
Short Interest219.93 thousand
Float14.35 million
Short Ratio1.96
Market Cap$77.13 million
Market Maker ActivityDaily Short Volume

News

02-23-2018
FDA approves KemPharm's Apadaz (SeekingAlpha)
02-20-2018
Correcting The Record On KemPharm (SeekingAlpha)
02-16-2018
Key events next week - healthcare (SeekingAlpha)
02-12-2018
Wall Street Breakfast: Infrastructure Details Coming Today (SeekingAlpha)
02-11-2018
OxyContin maker stops promoting opioids (SeekingAlpha)
11-30-2017
Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition (SeekingAlpha)
11-25-2017
Ignore The Pain And Get A (Portfolio) Stimulant With KemPharm (SeekingAlpha)
11-21-2017
FDA issues guidance on development of generic abuse-deterrent opioids (SeekingAlpha)
11-20-2017
Cost of U.S. opioid epidemic tops $500B (SeekingAlpha)
11-12-2017
KemPharm 2017 Q3 - Results - Earnings Call Slides (SeekingAlpha)


Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 36.9%

Earnings Stats

PE Ratio -1.99
Dividend Yield 0%
Peer EarningsEarnings Calendar

Technicals

200 Day Moving Average $3.97
50 Day Moving Average $5.05
52 Week High $6.75
52 Week Low $2.45



Data provided for free by IEX. Questions? Read the FAQ